Reem Jan is a clinical Associate Professor at the University of Chicago, with extensive experience in the diagnosis and management of rheumatic diseases in a tertiary care setting. She graduated from St George's medical school in London UK, completed internal medicine residency and rheumatology fellowship at the University of Michigan in Ann Arbor before her academic appointment in Chicago in 2012. She has developed particular expertise in spondyloarthritis, with focus on ankylosing spondylitis and psoriatic arthritis. She provides specialist rheumatology care for patients followed at the University of Chicago Inflammatory Bowel Disease Center, which forms her primary research interest. She also has a senior administrative role within the Department of Medicine as Associate Chief of Clinical Affairs for the section of Rheumatology.
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center Study.
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center Study. Arthritis Care Res (Hoboken). 2025 Jun; 77(6):777-784.
PMID: 39748206
Screening for Spondyloarthritis in Patients with Inflammatory Bowel Disease - SPARTAN 2024 Annual Meeting Proceedings.
Screening for Spondyloarthritis in Patients with Inflammatory Bowel Disease - SPARTAN 2024 Annual Meeting Proceedings. Curr Rheumatol Rep. 2025 Feb 01; 27(1):17.
PMID: 39891807
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease.
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2025 Oct 01; 120(10):2330-2338.
PMID: 39760386
Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis.
Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis. Life (Basel). 2023 Mar 02; 13(3).
PMID: 36983834
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics. Pharmaceuticals (Basel). 2023 Feb 08; 16(2).
PMID: 37259404
Study protocol for a pilot randomized, double-blind, placebo-controlled trial to investigate the anti-inflammatory effects of Frondanol in adults with inflammatory bowel disease.
Study protocol for a pilot randomized, double-blind, placebo-controlled trial to investigate the anti-inflammatory effects of Frondanol in adults with inflammatory bowel disease. Contemp Clin Trials Commun. 2023 Feb; 31:101046.
PMID: 36544548
Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction: Observations from the Gulf acute heart failure registry (Gulf CARE).
Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction: Observations from the Gulf acute heart failure registry (Gulf CARE). Medicine (Baltimore). 2022 Jun 10; 101(23):e29452.
PMID: 35687781
Management of Gout.
Management of Gout. JAMA. 2021 Dec 28; 326(24):2519-2520.
PMID: 34962547
IgG-4-Related Hypophysitis Treated With Rituximab: Case Report.
IgG-4-Related Hypophysitis Treated With Rituximab: Case Report. J Clin Rheumatol. 2021 Dec 01; 27(8S):S340-S341.
PMID: 33264241
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proc Natl Acad Sci U S A. 2020 01 07; 117(1):552-562.
PMID: 31871193